Truist Financial Keeps Their Buy Rating on Alnylam Pharma (ALNY)
Truist Financial analyst Danielle Brill maintained a Buy rating on Alnylam Pharma today and set a price target of $530.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Brill is a 5-star analyst with an average return of 14.1% and a 56.15% success rate. Brill covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Disc Medicine, and Centessa Pharmaceuticals.
In addition to Truist Financial, Alnylam Pharma also received a Buy from Oppenheimer’s Kostas Biliouris in a report issued yesterday. However, on January 6, Wells Fargo maintained a Hold rating on Alnylam Pharma (NASDAQ: ALNY).
Based on Alnylam Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.25 billion and a net profit of $251.08 million. In comparison, last year the company earned a revenue of $500.92 million and had a GAAP net loss of $111.57 million
Read More on ALNY:
Disclaimer & DisclosureReport an Issue
- Alnylam price target lowered to $530 from $535 at Truist
- Alnylam assumed with an Outperform at Oppenheimer
- Alnylam price target lowered to $491 from $525 at Bernstein
- Alnylam: Buy Rating Reaffirmed as Long-Term TTR Growth and Strategic Update Offset Near-Term Amvuttra Launch Concerns
- Alnylam to invest $250M to expand manufacturing facility in Massachusetts
